ライフサイエンスコーパス: iodine-125

1 Iodine-125-12-[m-iodophenyl]-dodecylphosphocholine (NM-3

2 R was measured by using urinary clearance of iodine 125 ((125)I) iothalamate.

3 Iodine 125 ((125)I)-labeled FIAU was used in vitro and i

4 Iodine 125 ((125)I)-labeled fibrin microparticles inject

5 1 immobilized on Sepharose beads and soluble iodine 125 ((125)I)-labeled fibrinogen demonstrated no s

6 F immobilized on Sepharose beads and soluble iodine 125 ((125)I)-labeled fibrinogen demonstrated satu

7 and HER2-targeted indium 111 ((111)In)- and iodine 125 ((125)I)-labeled panitumumab and trastuzumab,

8 tic brachytherapy (SBT) with implantation of iodine-125 ((125)I) seeds as a safe and effective local

9 -coated surfaces followed by the addition of iodine 125 (125I) monoclonal antibodies (mAbs) directed

10 ancer patients were treated with radioactive iodine 125 (125I) prostate implants followed by external

11 It was labeled with iodine-125 (125I) to trace the concentration of antibody

12 onkey (Macaca mulatta) was assessed by using iodine 125 ([125I)-Tyr0]-sauvagine with or without the s

13 n strand cleavage by the Auger radiodecay of iodine 125, allows us to determine the distances between

14 Biodistribution studies of the iodine-125 analogue showed 3% ID/g in LNCaP xenograft tu

15 Iodine-125 and palladium-103 are each reasonable isotope

16 rbidities, type of isotope (ruthenium 106 or iodine 125), and initial VA ( >20/50 or <20/50).

17 BVM) were synthesized, exchange-labeled with iodine-125, and evaluated as possible in vivo markers fo

18 nd-guided TIPPB with either palladium-103 or iodine-125 as monotherapy or combined with external radi

19 For the iodine-125 brachytherapy and endoresection groups, respe

20 atients with choroidal melanoma treated with iodine-125 brachytherapy and intraoperative FNAB from Ja

21 ngle choroidal tumor, which was treated with iodine-125 brachytherapy and underwent intraoperative fi

22 ic spread was observed in 11 patients in the iodine-125 brachytherapy group vs only 1 patient in the

23 al tumor location with 54 cases treated with iodine-125 brachytherapy.

24 atients treated with either endoresection or iodine-125 brachytherapy.

25 with outcomes similar to those obtained with iodine-125 brachytherapy.

26 istorical controls treated with surgery plus iodine-125 brachytherapy.

27 Plaque radiotherapy with iodine-125, cobalt-60, iridium-192, or ruthenium-106.

28 Iodine-125 HPP-forskolin and [3H]cytochalasin B did not

29 Iodine-125 HPP-forskolin and [3H]cytochalasin B did not

30 if a greater tumor regression response after iodine 125 (I(125)) brachytherapy correlates with class

31 A total of 1201 patients that underwent iodine-125 (I-125) EPBT as primary treatment for PUM bet

32 Iodine-125-IACFT was prepared in > 60% radiochemical yie

33 d glomerular filtration rate measured by the iodine-125 iothalamate (Glofil) test and renal biopsy fi

34 Iodine-125-IUdR was infused intracerebrally over a 2-day

35 ons for selective binding of the radioligand iodine 125-labeled (R)-trans-7-hydroxy-2-[N-propyl-N-(3'

36 etermine the maximum-tolerated dose (MTD) of iodine 125-labeled monoclonal antibody A33 (125I-mAb A33

37 Biodistribution studies of the iodine-125-labeled compounds in MDA-MB-231 mouse xenogra

38 Immunoprecipitation assays with iodine-125-labeled epibatidine and solubilized human neu

39 Iodine-125-MAbs provided quantification of circulating a

40 iary body or choroidal melanoma treated with iodine 125 or ruthenium 106 episcleral brachytherapy bet

41 diately before implantation of a radioactive iodine 125 plaque as treatment for the tumor.

42 Low-dose iodine-125 plaque brachytherapy (67.5-81 Gy at tumor ape

43 Transscleral FNAB at the time of iodine-125 plaque brachytherapy was not associated with

44 Iodine-125 plaque brachytherapy.

45 Custom-designed iodine-125 plaque radiotherapy delivering planned 8000 c

46 Iodine-125 plaque radiotherapy is effective in the manag

47 Iodine-125 plaque radiotherapy provides adequate tumor c

48 Custom designed iodine-125 plaque radiotherapy.

49 er surgical resection that were treated with iodine-125 plaque radiotherapy.

50 ry 1, 1990, through December 30, 2010, using iodine 125 plaques and treatment simulation software dev

51 Radiolabeled with iodine-125, Rho-FF-Van shows strong radioactive signal i

52 selective removal of the clipped node using iodine-125 seed localization.

53 Iodine-125-T101 (100 micrograms, 1 ml) was mixed with 90